Search results
Results from the WOW.Com Content Network
Specialty professional organizations recommend that people take the lowest effective PPI dose to achieve the desired therapeutic result when used to treat gastroesophageal reflux disease long-term. [ 20 ] [ 21 ] [ 22 ] In the United States, the Food and Drug Administration (FDA) has advised that over-the-counter PPIs, such as Prilosec OTC ...
Antacids, H2 blockers (which work to reduce stomach acid), and proton pump inhibitors (PPIs) may provide relief from acid reflux symptoms. However, always consult a healthcare professional before ...
These drugs are among the most widely sold drugs in the world, and are generally considered effective. [3] When these medications are used long term, the lowest effective dose should be taken. [4] They may also be taken only when symptoms occur in those with frequent problems. [5] Proton-pump inhibitors are named using the suffix "-prazole".
This includes an upset stomach, heartburn or other similar symptoms. Bismuth subsalicylate has the empirical chemical formula C 7 H 5 BiO 4 , [ 1 ] and is a colloidal substance obtained by hydrolysis of bismuth salicylate (Bi(C 6 H 4 (OH)CO 2 ) 3 ).
Omeprazole, sold under the brand names Prilosec and Losec, among others, is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. [1] It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. [1]
For premium support please call: 800-290-4726 more ways to reach us
Rabeprazole, sold under the brand name Aciphex, among others, is a medication that decreases stomach acid. [6] It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and excess stomach acid production such as in Zollinger–Ellison syndrome. [6]
A 14-day course of "quadruple therapy" with a proton pump inhibitor, bismuth, tetracycline, and metronidazole or tinidazole is a more complicated but also more effective regimen. In a 2011 randomized, controlled trial, the per protocol eradication rates were 93% with quadruple therapy and 70% with triple therapy.